Status:
COMPLETED
Formula Tolerance of Term Infants
Lead Sponsor:
Abbott Nutrition
Conditions:
Gastro-Intestinal Tolerance
Eligibility:
All Genders
7-65 years
Phase:
NA
Brief Summary
To assess the effects of infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants
Eligibility Criteria
Inclusion
- Participant is judged to be in good health as determined from participant's medical history by parent report
- Participant is a singleton from a full-term birth with a gestational age of 37-42 weeks.
- Participant's birth weight was \>= 2490 g (\~5 lbs. 8 oz.)
- Participant was identified by parents as very fussy or extremely fussy in the Baseline Tolerance Evaluation on a formula-feed
- Participant is exclusively formula-fed at time of study entry and Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study, unless instructed otherwise by their healthcare professional.
- Parent(s) confirm their intention not to administer vitamin, mineral, human milk oligosaccharide(s) (HMO), prebiotic(s), or probiotic(s) supplements (with the exception of vitamin D supplements if instructed by their healthcare professional), non-study formula, foods, juices, or other sources of nutrition to their infant from enrollment through the duration of the study
- Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) and provided applicable local privacy regulation authorization prior to any participation in the study
Exclusion
- An adverse maternal, fetal, or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. This includes but is not limited to suspected maternal substance abuse.
- Participant is taking and plans to continue taking medications (including OTC, such as Mylicon® for gas), home remedies (such as juice for constipation), herbal preparations, or rehydration fluids that might affect GI tolerance.
- Participant participates in another study that has not been approved as a concomitant study
- Participant has been fed a formula with greater than 2 HMOs prior to study enrollment
- Participant has been fed an extensively hydrolyzed, amino acid based, or preterm formula within 14 days prior to study enrollment and/or an extensively hydrolyzed, amino acid based, or preterm formula has been recommended by the physician.
- Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent
- Participant has been treated with antibiotics within 7 days prior to enrollment
Key Trial Info
Start Date :
July 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 22 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04915937
Start Date
July 13 2021
End Date
November 22 2022
Last Update
December 20 2022
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
MedPharmics, LLC
Phoenix, Arizona, United States, 85015
2
Dade Research Center, LLC
Miami, Florida, United States, 33126
3
Meridian Clincial Research- Macan
Macon, Georgia, United States, 31210
4
Clinical Research Prime
Idaho Falls, Idaho, United States, 83404